Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Press Metal Q2 profit rises 7%

2018-08-16 thestar.com.my
In a statement, group chief executive officer Tan Sri Paul Koon(pic) said external uncertainties continue to exist in the global supply chain as a result of United States tariffs and sanctions, and this is amplified by the ongoing alumina supply disruptions.
7216 8869

0
Small-cap stocks rebound after falling 24%

2018-07-26 thestar.com.my
Long-term value: CIMB Research reckons that despite the uncertainties in the market, small-cap stocks offer long-term value accretion to investors
7216 BSMAF 8079 7035 1818

0
Small-cap stocks offer investors stronger growth prospects, says CIMB Research

2018-07-25 theedgemarkets
KUALA LUMPUR (July 25): Small capitalised (small caps) stocks have the potential to generate returns the long run despite having underperformed so far this year, according to CIMB Research.
7216 5703 4405 7246 8079 7035

0
KLCI dips 0.24% in line with regional markets

2018-07-23 theedgemarkets
KUALA LUMPUR (July 23): The FBM KLCI dipped 0.24% at mid-morning today, tracking regional losses, weighed by select index-linked blue chips.
7172 UPBMF 7006 2089 5014 9334 6033 5101 LIIHF 7123 KLKBY 5238 2445 4588 PNADF 5738 7216 0026 MYPRY 2836 PNAGF

0
KLCI drifts lower, tracks regional losses

2018-07-23 theedgemarkets
KUALA LUMPUR (July 23): The FBM KLCI drifted lower this morning, tracking regional markets, weighed by select blue chips.
KLKBY 2445 4588 5183 1589 7216 PECGF

0
Kawan Food to produce ‘fresh-frozen’ breads

2018-06-18 theedgemarkets
Kawan Food Bhd (June 14, RM2.35) Maintain add with an unchanged target price (TP) of RM3.14: At the end of last week, we arranged a teleconference call for Kawan Food Bhd managing director Timothy Tan with around 20 buy-side fund managers and analysts. The company indicated that almost all the required government approvals for its new factory have been secured and it is just waiting for a halal certification from the Malaysian Islamic Development Department (Jakim).
7216

0
Kawan Food’s RM200m factory set to start in July

2018-06-13 thestar.com.my
CIMB Research cited that one new product Kawan is looking at launching is wholemeal paratha bread.
7216

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...